IBA (Ion Beam Applications S.A.) has signed a strategic contract with Telix Pharmaceuticals to supply four Cyclone KIUBE cyclotrons to bolster production capacity. These advanced systems are scheduled for installation at selected RLS Radiopharmacies (RLS) facilities across the United States. The agreement marks a significant step in Telix's strategy to expand its manufacturing footprint for precision oncology treatments within the U.S. market. By increasing production capacity, Telix aims to accelerate the development and distribution of innovative nuclear medicine solutions. For IBA, the deal represents a confirmed equipment sale and reinforces its position as a leading provider of radiopharmaceutical technology. This partnership reflects positive operational momentum for both companies as they address the growing demand in the oncology sector.
Sign up free to access this content
Create Free Account